In humans, treatment of hypertension with a mineralocorticoid receptor antagonist additionally to an angiotensin I-converting enzyme blocker or an AT1R-blocker, also resulted in reduction of albuminuria/proteinuria [58]. This evidence concerns the gene NR3C2 and Hypertension.